Form 4 for RYTM RHYTHM PHARMACEUTICALS, INC.
Accepted 2024-11-13 00:00:00 ET · period of report 2024-11-11 · accession 0001104659-24-117941 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-11-13 | 2024-11-11 | RYTM | Shulman Joseph | Chief Technical Off | S - Sale+OE | $66.43 | -13.3K | 0 | -100% | -$882.3K |
| DM | 2024-11-13 | 2024-11-11 | RYTM | Shulman Joseph | Chief Technical Off | M - OptEx | $12.63 | +13.3K | 7,969 | New | +$167.8K |
| DM | 2024-11-13 | 2024-11-11 | RYTM | Shulman Joseph | Chief Technical Off | M - OptEx | $0.00 | -13.3K | 19.9K | -40% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-11 | S | D | 6,604 | $65.73 | 6,677 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $65.35 to $66.3499. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2024-11-11 | M | A | 5,312 | $21.38 | 13,281 | D | — | — | |
| 3 | Common | Common Stock | 2024-11-11 | M | A | 7,969 | $6.80 | 7,969 | D | — | — | |
| 4 | Common | Common Stock | 2024-11-11 | S | D | 5,977 | $67.05 | 700 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $66.5 to $66.4999. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2024-11-11 | S | D | 700 | $67.83 | 0 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $67.51 to $68.5099. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 6 | Derivative | Stock Option (right to buy) | 2024-11-11 | M | D | 5,312 | $0.00 | 0 | D | $21.38 · — to 2030-07-26 | 5,312 Common Stock | (F6) The stock options were granted on July 27, 2020. 25% of the shares subject to the option vested and became exercisable on July 27, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. |
| 7 | Derivative | Stock Option (right to buy) | 2024-11-11 | M | D | 7,969 | $0.00 | 19,922 | D | $6.80 · — to 2032-02-08 | 7,969 Common Stock | (F5) The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |